Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/23999
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-01-11T09:07:18Z-
dc.date.available2022-01-11T09:07:18Z-
dc.date.issued2006-05-
dc.identifier.citationErsoy, A. vd. (2006). ''Is glucocorticoid-induced osteonecrosis after kidney transplantation related to osteoporosis?''. Nephrology Dialysis Transplantation, 21(5), 1452-1453.en_US
dc.identifier.issn0931-0509-
dc.identifier.urihttps://doi.org/10.1093/ndt/gfi342-
dc.identifier.urihttps://academic.oup.com/ndt/article/21/5/1452/1822097-
dc.identifier.urihttp://hdl.handle.net/11452/23999-
dc.description.abstractOsteopenia and osteonecrosis (ON) cause important longterm morbidity in renal transplant (Tx) recipients with increasing incidences because of longer graft survival and related drug exposure. A 38-year-old woman who started on haemodialysis in November 2001 had a renal Tx from a live relative in March 2003 due to chronic pyelonephritis with vesicoureteral reflux related end-stage renal disease. She had persistent secondary amenorrhoea 2 months before dialysis treatment. Throughout this period she had calcitriol and phosphorus binders for controlling secondary hyperparathyroidism. Her pre-Tx serum parathyroid hormone (PTH) was 73.2 pg/ml and body mass index (BMI) was 18.4 kg/m2 . Post-Tx immunosuppressive treatment was prednisolone (500 mg initially, then 30 mg/day), tapered to 25 mg/day by postoperative day 14, mycophenolate mofetil (2 g/day), cyclosporin (CsA; 100 mg/d) and daclizumab (a dose of 1 mg/kg, totalling five dosages with 2-week intervals). After an uneventful 4 weeks she complained of severe leg pain and symptoms of muscle weakness in the previous 4 days. The dose of prednisolone was tapered to 15 mg/day, but pain developed in both shoulders. Diffuse ON was diagnosed by hip and shoulder magnetic resonance imagings (MRI). At the time of diagnosis the total cumulative doses of prednisolone and CsA were 1220 mg and 2925 mg in 4 weeks, respectively. Serum creatinine was 0.7 mg/dl, calcium 10.5 mg/dl, Alkaline phosphatase (ALP) 271 IU/l, PTH 84 pg/ml, calcitonin 27 pg/ml and calcitriol 22.9 ng/dl. Bone mineral densities (BMD) of the lumbar spine and the hip region by Dual x-ray absorptiomtery (DEXA) after post-Tx 8 weeks were evaluated as osteoporosis with T scores of 3.2 and 3.9, respectively. Oral calcium, calcitriol and alendronate were added to the treatment. Her complaints regressed within 10 days. The dose of prednisolone was tapered to 10 mg/day at month 4 and to 5 mg/day at month 10. One year later, hip and shoulder MRIs showed normal findings. The respective post-Tx T scores of the lumbar spine and the femoral neck improved from -2.8 and -3.5 in the first year to -2.4 and -2.2 in the second year. Her serum creatinine level was 0.8 mg/dl with no complaint.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectTransplantationen_US
dc.subjectUrology & nephrologyen_US
dc.subjectKidney transplantationen_US
dc.subjectKidney failure, chronicen_US
dc.subjectHumansen_US
dc.subjectGlucocorticoidsen_US
dc.subjectFemur head necrosisen_US
dc.subjectFemaleen_US
dc.subject.meshTransplantation immunologyen_US
dc.subject.meshSeverity of illness indexen_US
dc.subject.meshRisk assessmenten_US
dc.subject.meshPrognosisen_US
dc.subject.meshOsteoporosisen_US
dc.subject.meshMagnetic resonance imagingen_US
dc.subject.meshKidney transplantationen_US
dc.subject.meshKidney failure, chronicen_US
dc.subject.meshHumansen_US
dc.subject.meshGlucocorticoidsen_US
dc.subject.meshFemur head necrosisen_US
dc.subject.meshFemaleen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshDensitometry, X-rayen_US
dc.subject.meshAdulten_US
dc.titleIs glucocorticoid-induced osteonecrosis after kidney transplantation related to osteoporosis?en_US
dc.typeArticleen_US
dc.identifier.wos000237004900063tr_TR
dc.identifier.scopus2-s2.0-33646178815tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.orcid0000-0001-7482-668Xtr_TR
dc.identifier.startpage1452tr_TR
dc.identifier.endpage1453tr_TR
dc.identifier.volume21tr_TR
dc.identifier.issue5tr_TR
dc.relation.journalNephrology Dialysis Transplantationen_US
dc.contributor.buuauthorErsoy, Alparslan-
dc.contributor.buuauthorKahvecioğlu, Serdar-
dc.contributor.buuauthorErsoy, Canan-
dc.contributor.buuauthorAkdağ, İbrahim-
dc.contributor.buuauthorYurtsever, İsmail-
dc.contributor.buuauthorDilek, Kamil-
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.identifier.pubmed16357048tr_TR
dc.subject.wosTransplantationen_US
dc.subject.wosUrology & nephrologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ1 (Urology & nephrology)en_US
dc.wos.quartileQ2 (Transplantation)en_US
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid55956719500tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid8342488100tr_TR
dc.contributor.scopusid8535041400tr_TR
dc.contributor.scopusid56005080200tr_TR
dc.subject.scopusKienboeck Disease; Femur Head Necrosis; Thighsen_US
dc.subject.emtreePrednisoloneen_US
dc.subject.emtreePhosphate binding agenten_US
dc.subject.emtreeParathyroid hormoneen_US
dc.subject.emtreeMycophenolic acid 2 morpholinoethyl esteren_US
dc.subject.emtreeGlucocorticoiden_US
dc.subject.emtreeDaclizumaben_US
dc.subject.emtreeCyclosporin Aen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeCalciumen_US
dc.subject.emtreeCalcitriolen_US
dc.subject.emtreeCalcitoninen_US
dc.subject.emtreeAlkaline phosphataseen_US
dc.subject.emtreeAlendronic aciden_US
dc.subject.emtreeVesicoureteral refluxen_US
dc.subject.emtreeShoulder painen_US
dc.subject.emtreeSecondary hyperparathyroidismen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeParathyroid hormone blood levelen_US
dc.subject.emtreeOsteoporosisen_US
dc.subject.emtreeNuclear magnetic resonance imagingen_US
dc.subject.emtreeMuscle weaknessen_US
dc.subject.emtreeLumbar spineen_US
dc.subject.emtreeLetteren_US
dc.subject.emtreeLeg painen_US
dc.subject.emtreeKidney transplantationen_US
dc.subject.emtreeKidney graft rejectionen_US
dc.subject.emtreeKidney failureen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHipen_US
dc.subject.emtreeHemodialysisen_US
dc.subject.emtreeFemur necken_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeDual energy X ray absorptiometryen_US
dc.subject.emtreeDrug dose regimenen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeChronic pyelonephritisen_US
dc.subject.emtreeCase reporten_US
dc.subject.emtreeCalcium blood levelen_US
dc.subject.emtreeCalcitonin blood levelen_US
dc.subject.emtreeBone necrosisen_US
dc.subject.emtreeBone densityen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeAmenorrheaen_US
dc.subject.emtreeAlkaline phosphatase blood levelen_US
dc.subject.emtreeAdulten_US
Appears in Collections:Web of Science

Files in This Item:
File Description SizeFormat 
Ersoy_vd_2006.pdf180.07 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons